RXRX Q1 2021 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M

Gross Profit

$3M100.0% margin

Operating Income

-$30M-1219.4% margin

Net Income

-$31M-1228.7% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-2.0%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$50M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$272M

Total Liabilities

$505M

Stockholders' Equity

-$233M

Cash & Equivalents

$214M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$0	—
Gross Profit	$3M	$0	—
Operating Income	-$30M	-$18M	-66.2%
Net Income	-$31M	-$18M	-66.7%

Revenue Segments

License and Service

$3M98%

Grant

$62,0002%